What should animal models of depression model?

Neuroscience and Biobehavioral Reviews

Volumn 29, Issue 4-5, 2005, Pages 515-523

  Frazer, Alan ^a,b   Morilak, David A ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; PAROXETINE; VENLAFAXINE;

AFFECT; ANXIETY; ANXIETY DISORDER; BEHAVIOR; CLINICAL TRIAL; COGNITION; CONVALESCENCE; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; MEDICAL LITERATURE; NEUROBIOLOGY; NEUROSIS; NONHUMAN; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGY; RATING SCALE; REGULATORY MECHANISM; REVIEW; SYMPTOM; SYMPTOMATOLOGY; SYNDROME; TIME;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; HUMANS; TIME FACTORS;

EID: 19844375273     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2005.03.006     Document Type: Review

References (88)

1. C.A. Altar, R.E. Whitehead, R. Chen, G. Wortwein, and T.M. Madsen Effects of electroconvulsive seizures and antidepressants drugs on brain-derived neurotrophic factor protein in rat brain Biol. Psychiatry 54 2003 703 709
2. F. Artigas Limitations to enhancing the speed of onset of antidepressants - are rapid action antidepressants possible? Hum. Psychopharmacol. 16 2001 29 36
3. G. Aston-Jones, C. Chiang, and T. Alexinsky Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilance Prog. Brain Res. 88 1991 501 520
4. G. Aston-Jones, J. Rajkowski, and J. Cohen Locus coeruleus and regulation of behavioral flexibility and attention Prog. Brain Res. 126 2000 165 182
5. K. Brady, T. Pearlstein, G.M. Asnis, D. Baker, B. Rothbaum, C.R. Sikes, and G.M. Farfel Efficacy and safety of sertraline tretment of posttraumatic stress disorder: A randomized controlled trial JAMA 283 2000 1837 1844
6. O. Brawman-Mintzer Generalized anxiety disorder: Pharmacologic treatment of generalized anxiety disorder Psychiatric Clin. North America 24 2001 1 17
7. T.A. Brown, B.F. Chorpita, and D.H. Barlow Structural relationships among dimensions of the DSM-IV anxiety and mood disorders and dimensions of negative affect, positive affect, and autonomic arousal J. Abnorm. Psychol. 107 1998 179 192
8. M. Cecchi, H. Khoshbouei, M. Javors, and D.A. Morilak Modulatory effects of norepinephrine in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress Neuroscience 112 2002 13 21
9. 1-receptors in the central nucleus of the amygdala, on behavioral and neuroendocrine responses to acute immobilization stress Neuropharmacology 43 2002 1139 1147
10. L.A. Clark, and D. Watson Tripartite model of anxiety and depression: evidence and taxonomic implications J. Abnorm. Psychol. 100 1991 316 336
11. A.L. Coppell, Q. Pei, and T.S.C. Zetterstrom Bi-phasic change in BDNF gene expression following antidepressant drug treatment Neuropharmacology 44 1996 903 910
12. W. Coryell, A. Coppen, V.E. Zeigler, and J.T. Biggs: Early improvement as a predictor of response to amitriptyline and nortriptyline: a comparision of two patient samples Psychol. Med. 12 1982 135 139
13. P.L. Delgado, and F.A. Moreno Role of norepinephrine in depression J. Clin. Psychiatry 1 Suppl. 61 2000 5 12
14. P.L. Delgado, H.L. Miller, R.M. Salomon, J. Licinio, J.H. Krystal, F.A. Moreno, G.R. Heninger, and D.S. Charney Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of action of antidepressant action Biol. Psychiat. 46 1999 212 220
15. M.J. Detke, M. Rickels, and I. Lucki Active behaviors in the rat forced simming test differentially produced by serotonergic and noradrenergic antidepressants Psychopharmacology 121 1995 66 72
16. D.P. Devanand Camorbid pyschiatric disorders in late life depression Biol. Psychiatry 51 2002 236 242
17. R.S. Duman, G.R. Heninger, and E.J. Nestler A molecular and cellular theory of depression Arch. Gen. Psychiatry 54 1997 597 606
18. J. Fawcett, and R.L. Barkin Meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety J. Clin. Psychiatry 59 1998 123 127
19. J.M. Ferguson, J. Mendels, and G.E. Schwart Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression Int. Clin. Psychopharmacol. 17 2002 45 51
20. E. Frank, and M.E. Thase Natural history and preventative treatment of recurrent mood disorders Annu. Rev. Med. 50 1999 453 468
21. E. Frank, D.J. Kupfer, J.M. Perel, C. Cornes, D.B. Jarrett, A.G. Mallinger, M.E. Thase, A.B. McEachran, and V.J. Grochocinski Three-year outcomes for maintenance therapies in recurrent depression Arch. Gen. Psychiatry 47 1990 1093 1099
22. A.J. Gelenberg, and C.L. Chesen How fast are antidepressants? J. Clin. Psychiatry 61 2000 712 721
23. M.A. Geyer Animal models of psychiatric disorders F.E. Bloom D.J. Kupfer Psychopharmacology: The fourth generation of progress 68 1995 Raven Press, Ltd New York 787 798
24. J.M. Gorman Comorbid depression and anxiety spectrum disorders Depress Anxiety 4 1997 160 168
25. R.M.A. Hirschfeld Clinical importance of long-term antidepressant treatment Br. J. Psychiatry 179 Suppl. 42 2001 S4 S8
26. Z.P. Horovitz, P.W. Ragozzino, and R.C. Leaf Selective block of rat mouse-killing by antidepressants Life Sci. 4 1965 1909 1912
27. B.L. Jacobs, E.D. Abercrombie, C.A. Fornal, E.S. Levine, D.A. Morilak, and I.L. Stafford Single-unit and physiological analyses of brain norepinephrine function in behaving animals Prog. Brain Res. 88 1991 159 165
28. J.A. Jesberger, and J.S. Richardson Animal models of depression: parallels and correlates to severe depression in humans Biol. Psychiatry 20 1985 764 784
29. R. Jouvent, J. Le Houezec, C. Payan, H. Mikkelsen, J. Fermanian, V. Millet, and H. Dufour Dimensional assessment of onset of action of antidepressants: a comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and pyschomotor retardation Psychiatry Res. 79 1998 267 275
30. A.M. Kanner, and A. Balabanov Depression and epilepsy: How closely related are they? Neurology 58 2002 S37 S39
31. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J. Am. Stat. Assoc. 53 1958 457 481
32. S. Kasper, and E. Resinger Panic disorder: The place of benzodiazepines and selective serotonin reuptake inhibitors Eur. Neuropsychopharmacol. 11 2001 307 321
33. W.J. Katon Clinical and health services relationships between major depression, depressive symptoms, and general medical illness Biol. Psychiatry 54 2003 216 226
34. M.M. Katz, S.H. Koslow, N. Berman, S. Secunda, J.W. Maas, R. Casper, J. Kocsis, and P. Stokes A multi-vantaged approach to measurement of behavioral and affect states for clinical and psychobiological research Psychol. Rep. 55 1984 619 671
35. M.M. Katz, S.H. Koslow, and A. Frazer Onset of antidepressant activity: Reexamining the structure of depression and multiple actions of drugs Depression and Anxiety 4 1996, 1997 257 267
36. M.M. Katz, J.L. Tekell, C.L. Bowden, S. Brannan, J.P. Houston, N. Berman, and A. Frazer Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression Neuropsychopharmacology 29 2004 566 579
37. M.M. Katz, S.H. Koslow, J.W. Maas, A. Frazer, C.L. Bowden, R. Casper, J. Croughan, J. Kocsis, and E. Redmond Jr The timing, specificity and clinical prediction of tricyclic drug effects in depression Psychol. Med. 17 1987 297 309
38. K.S. Kendler Major depression and generalised anxiety disorder: Same genes (partly) different environments-revisited Br. J. Psychiatry 168 Suppl. 30 1996 68 75
39. K.S. Kendler, E.E. Walters, M.C. Neale, R.C. Kessler, A.C. Heath, and L.J. Eaves The structure of the genetic and environmental risk factors for six major psychiatric disorders in women: phobia, generalized anxiety disorder, panic disorder, bulimia, major depression and alcoholism Arch. Gen. Psychiatry 52 1995 374 383
40. A. Khan, S. Cohen, S. Dager, D.H. Avery, and D.L. Dunner Onset of response in relation to outcome in depressed outpatients with placebo and imipramine J. Affect. Disord. 17 1989 33 38
41. R.J. Kleber A double-blind comparative study of desipramine hydrochloride and diazepam in the control of mixed anxiety/depression symptomatology J. Clin. Psychiatry 40 1979 165 170
42. R.F. Krueger The structure of common mental disorders Arch. Gen. Psychiatry 56 1999 921 926
43. R. Kuhn The treatment of depressive states with G 22355 (imipramine hydrochloride) Am. J. Psychiatry 115 1958 459 464
44. H. Kuhs, and R. Tölle Sleep deprivation therapy Biol Psychiatry 29 1991 1129 1148
45. E.M. Laska, and A. Siegel Characterizing onset in psychopharmacological clinical trials Psychopharmacol. Bull. 31 1995 29 35
46. R.H. Lenox, and A. Frazer Mechanism of action of antidepressants and mood-stabilizers K.L. Davis D. Charney J.T. Coyle C. Nemeroff Mechanism of action of antidepressants and mood-stabilizers Neuropsychopharmacology, The fifth generation of progress 2002 Lippincott Williams & Wilkins Philadelphia 1139 1163
47. E.J. Lenze, B.H. Mulsant, M.K. Shear, G.S. Alexopoulos, E. Frank, and C.F. Reynolds Comorbidity of depression and anxiety disorders in later life Depress. Anxiety 14 2001 86 93
48. I. Lucki The forced swimming test as a model for core and component behavioral effects of antidepressant drugs Behav. Pharmacol. 8 1997 523 532
49. R.B. Lydiard Irritable bowel syndrome, anxiety, and depression: what are the links? J. Clin. Pyschiatry 62 2001 38 45
50. W.M. McDonald, I.H. Richard, and M.R. DeLong Prevalence, etiology, and treatment of depression in Parkinson's Disease Biol. Psychiatry 54 2003 363 375
51. J.r. McKinney, T. W, and W.E. Bunney Animal model of depression. I. Review of evidence: Implications for research Arch. Gen. Psychiatry 21 1969 240 248
52. S. Mineka, D. Watson, and L.A. Clark Comorbidity of anxiety and unipolar mood disorders Annu. Rev. Psychol. 49 1998 377 412
53. D.A. Morilak, and B.L. Jacobs Noradrenergic modulation of sensorimotor processes in intact rats: The masseteric reflex as a model system J. Neurosci. 5 1985 1300 1306
54. Morilak, D. A., Frazer, A., 2004. Antidepressants and brain monoaminergic systems: A dimensional approach to understanding their behavioral effects in depression and anxiety disorders. Int. J. Neuropsychopharmacol. 7,193-218.
55. D.L. Musselman, E. Betan, H. Larsen, and L.S. Phillips Relationship of depression to diabetes types 1 and 2: Epidemiology, biology, and treatment Biol. Psychiatry 54 2003 317 329
56. H. Nagayama, H. Nagano, A. Ikezaki, and T. Tashiro Prediction of efficacy by 1-week test therapy in depression J. Affect. Disord. 23 1991 213 216
57. J.C. Nelson A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression Biol. Psychiatry 46 1999 1301 1308
58. C. Nemeroff Comorbidity of mood and anxiety disorders: The rule, not the exception Am. J. Psychiatry 159 2002 3 4
59. M. Nibuya, S. Morinobu, and R.S. Duman Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments J. Neurosci. 15 1995 7539 7547
60. A.A. Nierenberg, N.E. McLean, J.E. Alpert, J.J. Worthington, J.F. Rosenbaum, and M. Fava Early Nonresponse to fluoxetine as a preditor of poor 8-week outcome Am. J. Psychiatry 152 1995 1500 1503
61. C. Nystrom, and T. Hallstrom Double-blind comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients. Clinical aspects Acta Psychiatr. Scand. 72 1985 6 15
62. M.-C. Pardon, G.G. Gould, A. Garcia, L. Phillips, M.C. Cook, S.A. Miller, P.A. Mason, and D.A. Morilak Stress reactivity of the brain noradrenergic system in three rat strains differing in their neuroendocrine and behavioral responses to stress: Implications for susceptibility to stress-related neuropsychiatric disorders Neuroscience 115 2002 229 242
63. G. Parker, K. Roy, D.B. Menkes, J. Snowdon, P. Boyce, D. Grounds, B. Hughson, and C. Stringer How long does it take for antidepressant therapies to act? Australian and New Zealand J. Psychiatry 34 2000 65 70
64. R.D. Porsolt, G. Anton, N. Blavet, and M. Jalfre Behavioural despair in rats: A new model sensitive to antidepressant treatments Eur. J. Pharmacol. 47 1978 379 391
65. S.H. Preskorn Antidepressant drug selection: Critera and options J. Clin. Psychiatry 55 1994 6 22
66. F.M. Quitkin, J.G. Rabkin, D. Ross, and J.W. Stewart Identification of true drug response to antidepressants Arch. Gen. Psychiatry 41 1984 782 786
67. F.M. Quitkin, J.D. Rabkin, J.M. Markowitz, J.W. Stewart, P.J. McGrath, and W. Harrison Use of pattern analysis to identify true drug response: A replication Arch. Gen. Psychiatry 44 1987 259 264
68. F.M. Quitkin, P.J. McGrath, J.W. Stewart, K. Ocepek-Welikson, B.P. Taylor, E. Nunes, D. Deliyannides, V. Agosti, S.J. Donovan, E. Petkova, and D.F. Klein Chronological milestones to guide drug change when should clinicians switch antidepressants? Arch. Gen. Psychiatry 53 1996 785 792
69. T.W. Robbins From arousal to cognition: The integrative position of the prefrontal cortex Prog. Brain Res. 126 2000 469 483
70. R.L. Rudolph, L.F. Fabre, J.P. Feighner, K. Rickels, R. Entsuah, and A.T. Derivan A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression J. Clin. Psychiatry 59 1998 116 122
71. J. Sareen, and M. Stein A review of the epidemiology and approaches to the treatment of social anxiety disorder Drugs 59 2000 497 509
72. Y. Shirayama, A.C. Chen, S. Nakagawa, D.S. Russell, and R.S. Duman Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression J. Neurosci. 22 2002 3251 3261
73. J.A. Siuciak, D.R. Lewis, S.J. Wiegand, and R.M. Lindsay Antidepressant-like effect of brain-derived neurotrophic factor (BDNF) Pharmacol. Biochem. Behav. 56 1997 131 137
74. J.G. Small, V. Milstein, J.F. Kellams, and I.F. Small Comparative onset on improvement in depressive symptomatology with drug treatment electroconvulsive therapy, and placebo J. Clin. Psychopharmacol. Suppl. 6 1981 62S 69S
75. P. Soubrié Reconciling the role of central serotonin neurons in human and animal behavior Behav. Brain Sci. 9 1986 319 363
76. M.R. Spoont Modulatory role of serotonin in neural information processing: Implications for human psychopathology Psychol. Bull. 112 1992 330 350
77. S.M. Stahl, J. Mendels, and G.E. Schwartz Effects of reboxetine an anxiety, agitation, and insomnia: Results of a pooled evaluation of randomized clinical trials J. Clin. Psychopharmocol. 22 2002 388 392
78. H.H. Stassen, A. Delini-Stula, and J. Angst Time course of improvement under antidepressant treatment: A survival-analytical approach Eur. Neuropsychopharmacol. 3 1993 127 135
79. H.H. Stassen, J. Angst, and A. Delini-Stula Delayed onset of action of antidepressant drugs? Survey of results of Zurich Meta-Analyses Pharmaco-Psychiatry 29 1996 87 96
80. H.H. Stassen, J. Angst, and A. Delini-Stula Delayed onset of action of antidepressant drugs? Survey of recent results Eur. Psychiatry 12 1997 166 176
81. H.H. Stassen, J. Angst, and A. Delini-Stula Fluoxetine versus moclobemide: Cross-comparison between the time courses of improvement Pharmacopsychiatry 32 1999 56 60
82. T.H. Svensson Peripheral, autonomic regulation of locus coeruleus noradrenergic neurons in brain: Putative implications for psychiatry and psychopharmacology Psychopharmacology 92 1987 1 7
83. A. Szegedi, M.J. Muller, I. Anghelescu, C. Klawe, R. Kohnen, and O. Benkert Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression J. Clin. Psychiatry 64 2003 413 420
84. A. Szegedi, H. Wetzel, D. Angersbach, G.C. Dunbar, H. Schwarze, M. Philipp, and O. Benkert A double-blind study comparing paroxetine and maprotiline in depressed outpatients Pharmacopsychiatry 30 1997 97 105
85. G.D. Tollefson, and S.L. Holman How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo Int. Clin. Psychopharmacol. 9 1994 245 250
86. M.H. Trivedi, A.J. Rush, T.J. Carmody, R.M.J. Donahue, C. Bolden-Watson, T.L. Houser, and A. Metz Do bupropion SR and seratraline differ in their effects on anxiety in depressed patients J. Clin. Psychiatry 62 2001 776 781
87. D. Watson, L.A. Clark, K. Weber, J.S. Assenheimer, M.E. Strauss, and R.A. McCormick Testing a tripartite model: II exploring the symptom structure of anxiety and depression in student, adult, and patient samples J. Abnorm. Psychol. 104 1995 15 25
88. P. Willner Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation Psychopharmacology 134 1997 319 329